Trial Profile
An Australian, phase II , multicentre, randomised, dose intensification study investigating oral fludarabine, oral cyclophosphamide, and intravenous rituximab (poFCivR) tolerance in previously untreated elderly (=65years old) patients with chronic lymphocytic leukaemia. (CLL)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Rituximab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Acronyms OFOCIR
- 08 Feb 2021 Status changed from active, no longer recruiting to completed.
- 26 Apr 2018 Planned End Date changed from 31 Dec 2017 to 31 May 2018.
- 04 Dec 2010 Interim results presented at the 52nd Annual Meeting and Exposition of the American Society of Hematology